Tracking Healthcare Utilization (Cost) In Pseudobulbar affect Patients treated with Nuedexta

Pseudobulbar affect (PBA) is an underdiagnosed condition characterized by sudden, involuntary episodes of crying and/or laughing in patients with traumatic brain injury or certain neurologic diseases, including multiple sclerosis, amyotrophic lateral sclerosis, stroke, Alzheimer’s disease, and others. Studies suggest that PBA symptoms are associated with added healthcare utilization and costs. NUEDEXTA (dextromethorphan/quinidine) is the only FDA and EMA approved PBA treatment. The primary objective of this analysis is to evaluate healthcare utilization and costs in PBA patients before and after dextromethorphan/quinidine treatment.
Source: Value in Health - Category: Global & Universal Authors: Source Type: research